here. Also, reach out to us at <a href=https://www.iqvia.com/blogs/2024/03/"mailto:OrchestrateYourTrials@iqvia.com">OrchestrateYourTrials@iqvia.com to learn more about your clinical trial technology implementation strategy. </p>" /> here. Also, reach out to us at <a href=https://www.iqvia.com/blogs/2024/03/"mailto:OrchestrateYourTrials@iqvia.com">OrchestrateYourTrials@iqvia.com to learn more about your clinical trial technology implementation strategy. </p>" />
Blog
Insights into 2024
AI, Faster Trials and Why Interoperability Matters More Than Ever
Melissa Easy, VP of Clinical Technologies at IQVIA
Feb 27, 2024

In 2023, the healthcare industry witnessed numerous emerging trends, including the accelerated adoption of AI technologies in clinical trials. While proving promising, a new set of challenges have been introduced. From concerns about potential job displacement to heightened regulatory complexities to lack of cohesiveness across applications and systems.

In navigating the complex healthcare landscape this year, stakeholders are faced with the dual task of harnessing the potential of diverse solutions while overcoming the hurdles they may pose. While there are more challenges and predictions, I will focus on three key topics for consideration. I’ve outlined what 2024 has in store for the healthcare industry.

AI Set to Enhance, Not Replace

Contrary to ongoing discussions about AI displacing jobs, the use of AI tools marks a significant acceleration for humans across the clinical trials life cycle. In fact, this year and beyond, the integration of AI in clinical operations will enhance productivity and outcomes within trials, rather than replace human roles. With advanced tools such as generative AI, human capabilities are poised to be augmented, automating routine tasks and enabling professionals to focus on strategic aspects of their roles and engage in critical activities such as patient-facing tasks.

Generative AI’s increased adoption will also empower research sites with tools to address anticipated study start-up challenges in various phases of clinical trials. This encompasses heightened compliance with regulatory standards on a global scale, improved coordination among multiple sites and streamlined patient recruitment efforts. On the other hand, for sponsors, this development may translate to the ability to effectively identify and choose the most suitable sites for specific studies, guaranteeing adherence to the appropriate protocols and, ultimately, the successful launch of new trials.

All in all, the adoption of AI, rather than replacing jobs, will enable professionals to optimize time and resources and engage in critical trial operations, including patient-facing activities, that uniquely benefit from human input.


Accelerating Clinical Trial Speed and Agility Through Technology

At the core of clinical trials is the imperative to achieve faster and more precise outcomes. As more studies are projected to take place in hybrid and remote settings, many challenges will emerge, posing distinct obstacles for patients, sites and sponsors.

All through 2024, the effective recruitment of patients and the ability to personally connect with them will be a major undertaking. Additionally, sites and sponsors will aim to enhance quality and efficiency of data and overall clinical trials with the use of AI-powered technologies. These advanced tools will improve workflows, instrument patient-facing interactions and effectively collect study data. Strategies and solutions that empower all stakeholders with greater trial transparency and personalized experiences to optimize outcomes are critical. With the ability to analyze an increasingly vast volume of data, velocity and variety of information generated, AI and data analytics will deliver advanced insights faster and automate actions for quicker resolution to potential challenges.


Navigating Interoperability Challenges within Clinical Trials

There are a myriad of clinical trial technologies going to market, and coupled with a rapidly evolving clinical trial landscape, healthcare professionals are faced with the challenge of tracking and optimizing each technology adopted. In this context, the imperative for interoperability among trials is crucial to success.

Currently, siloed systems and inefficient processes are disrupting seamless collaboration. For instance, sites tell us they are managing up to 22 distinct systems daily across multiple studies – a striking example of the sheer number of technologies sites must interact with to conduct trials. The specific challenges associated with interacting with this volume of solutions range from transferring data across various systems to even the simple task of logging in to each one of them – which takes more time the more systems there are.

The segmentation of numerous technologies is compromising efficiency and jeopardizing the utilization of critical site data. As sponsors adopt new tools, we’ll begin to see healthcare professionals seek strategies that enable a harmonized, interoperable ecosystem.

This year, we’ll witness not only the adoption of advanced technologies including AI; it will mark the era when diverse tech stacks integrate and connect, driving a connected intelligence for users, ensuring efficient processes, improved collaboration and ultimately, the enhanced execution of impactful, patient-centric clinical trials.

At IQVIA, we’re working with healthcare professionals to assist them in accelerating their clinical trial processes and improve outcomes through our state-of-the-art AI-enhanced technology solutions. We are watching the trends discussed above closely to ensure we help organizations reap the most value from our solutions in 2024. Learn more about how these solutions are revolutionizing trial development here. Also, reach out to us at OrchestrateYourTrials@iqvia.com to learn more about your clinical trial technology implementation strategy.

Related solutions

Contact Us